本帖最后由 老马 于 2012-1-13 21:20 编辑 * H5 R" b7 k$ o3 d+ L' H' ~
4 a# n* H: @$ B, _5 G x爱必妥和阿瓦斯丁的比较
. Y+ Q2 l* C6 k. ~ F
8 M) E, y' ^* B9 n: h, @
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/: w. R/ L; S7 ]; M4 S
2 C0 T+ X/ n3 b4 ~- p6 x! z
. W _/ p9 z3 Q2 k6 _0 @! v
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/8 E) V5 `4 {% D6 g7 `- I
==================================================- l: | a. D% j; N. o
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
- V$ F4 N/ p5 Y3 ^Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.* ]9 s1 A& G( ?2 Q8 X
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
/ U" A/ Z2 u ]) T
|
显身卡
